Fixed-dose combination
Acyclovir and Hydrocortisone is a fixed-dose combination of a corticosteroid, a herpes simplex virus nucleoside analog DNA polymerase inhibitor and a herpes zoster virus nucleoside analog DNA polymerase inhibitor. MedsAcross supplies Acyclovir and Hydrocortisone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
XERESE, a combination of acyclovir, a herpes simplex virus deoxynucleoside analog DNA polymerase inhibitor, and hydrocortisone, a corticosteroid, is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older).
Source: US FDA prescribing information
Acyclovir is an antiviral drug active against α-herpesviruses and hydrocortisone is an anti-inflammatory drug.
Source: US FDA prescribing information
Topically apply XERESE 5 times per day for 5 days. Therapy should be initiated as early as possible after the first signs and symptoms (i.e., during the prodrome or when lesions appear). For each dose, topically apply a quantity of XERESE sufficient to cover the affected area, including the outer margin. Avoid unnecessary rubbing of the affected area to avoid aggravating or transferring the infection. For children 6 years of age and older, the dosage is the same as in adults.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
• Only for topical use for recurrent herpes labialis on the lips and around the mouth. General XERESE is intended for cutaneous use only for herpes labialis of the lips and around the mouth. XERESE should not be used in the eye, inside the mouth or nose, or on the genitals. There are other orofacial lesions, including bacterial and fungal infections, which may be difficult to distinguish from a cold sore. Patients should be encouraged to seek medical advice when a cold sore fails to heal within 2 weeks. XERESE has a potential for irritation and contact sensitization.
Source: US FDA prescribing information
The following most common adverse reactions (<1%) were local skin reactions: Drying or flaking of the skin, burning or tingling, erythema, pigmentation changes, application site reactions including signs and symptoms of inflammation.
Source: US FDA prescribing information
No drug interaction studies have been performed with XERESE.
Source: US FDA prescribing information
Store at controlled room temperature 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Acyclovir and Hydrocortisone, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Xerese 50 mg/10 mg per g creamTopical | Acyclovir and Hydrocortisone | Bausch Health | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 31 July 2009 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Acyclovir and Hydrocortisone and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Acyclovir and Hydrocortisone, including Xerese.
Yes. The US FDA first approved Acyclovir and Hydrocortisone on 31 July 2009, according to Drugs@FDA.
No listed presentation of Acyclovir and Hydrocortisone is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.